Tag Archive for: checkpoint blocker

PD-L1 blocks PD-L1 and B7.1 receptors on T cells thus triggering inactivation of cytotoxic T cells. © Genbentech Inc

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.